Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers

Niedźwiecki, Sebastian; Stępień, Tomasz; Kopec, Krzysztof; Kuzdak, Krzysztof; Komorowski, Jan; Krupiński, Roman; Stępień, H

doi:10.1016/j.cyto.2007.02.008

Cited by 31 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results concur to an extent with a previous report that measured serum angiopoietin levels in thyroid cancer patients [26]. In that report, thyroid cancer patients had lower serum Ang-1 and higher serum Ang-2 levels compared with controls, although the prognostic significance was not evaluated.…”

Section: Discussionsupporting

confidence: 92%

“…There are a few studies on serum Ang-1 levels, and these have reported conflicting results. Compared with the level in controls, the serum Ang-1 level was elevated in breast cancer [25] but lower in thyroid cancer [26]; the level was similar to the control level in prostate cancer [25] and acute myeloid leukemia [27].…”

Section: Introductionmentioning

confidence: 51%

“…The tissue expression level of Ang-2 is related to the stage progression and overall survival [23,24]. Serum Ang-2 has also been reported to be increased in breast cancer [25], prostate cancer [25], thyroid cancer [26], acute myeloid leukemia [27], and lung cancer [28], with prognostic implications in the latter two cancers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

et al. 2009

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 51%

See 1 more Smart Citation

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

et al. 2009

View full text Add to dashboard Cite

“…A previous study demonstrated that Ang1/Tie-2 system dysfunction may have an important role in thyroid carcinogenesis (16); however, the roles of Ang1 and Tie2 expression levels in PTC remain unclear. The present study detected miR-182 expression in 30 human PTC and adjacent normal tissues using RT-qPCR.…”

Section: Ang1 and Tie2 Expression In Ptc Tissues And Cell Linesmentioning

confidence: 99%

Ang1/Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K/AKT pathway

Yao

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The angiopoietin 1 (Ang1)/angiopoietin receptor (Tie2) signaling pathway may have a notable role in the pathogenesis of inflammatory diseases. The abnormal expression of angiopoietin 1 and Tie2 has also been reported in various malignant tumors, including papillary thyroid carcinoma (PTC). However, the role and mechanism of the Ang1/Tie2 pathway in the progression of PTC remains unclear. Therefore, the aims of the present study were to clarify this. Significantly high expression levels of Ang1 and Tie2 were observed in PTC tissues and cell lines. Furthermore, MTT and wound-healing assays revealed that the Ang1-mediated stimulation of human PTC cells resulted in increased proliferation and migration. Conversely, the downregulation of Tie2 levels using short hairpin RNA targeted at Tie2 abrogated the Ang1-mediated effect on cell proliferation and migration. In studying the expression of phosphoinositide-3 kinase (PI3K)/RAC serine/threonine-protein kinase (Akt) pathway, the upregulation of Ang1/Tie2 was found to be associated with the activation of the PI3K/Akt pathway in PTC. In conclusion, the data from the present study indicated that the Ang1/Tie2 induces PTC oncogenesis via the PI3K/Akt pathway, providing novel insights into human PTC therapy. IntroductionPapillary thyroid carcinoma (PTC) is the most prevalent histological thyroid carcinoma subtype, accounting for ~80% of cases (1,2). Although recent advances in diagnosis and treatment strategies have been made in clinical and experimental oncology, ≤30% of patients present with local/regional recurrence or distant metastasis within 10 years (2,3). Thus, the elucidation of the molecular mechanisms underlying PTC progression is urgently required in order to develop effective diagnostic, prognostic and therapeutic strategies.Receptor tyrosine kinases are cell surface proteins that transduce signals from extracellular growth factors intracellularly, to elicit biological responses (4). Receptor tyrosine kinases act as potent oncoproteins and are abnormally expressed in a number of cancer types, including gliomas (5). Angiopoietin-1 (Ang1) receptor (TEK, also known as Tie2) is a receptor tyrosine kinase that was identified as an endothelial-cell-specific receptor with a critical role in the modulation of vasculogenesis and remodeling (6). Tie2 expression occurs, and is partially maintained, during differentiation in human neural stem cells (7), but not in mature neurons (8). Dysregulated Tie2 expression has also been observed in several tumor tissues, including oral squamous cell carcinoma, breast, gastric, leukemia and thyroid cancer (9-13). These studies revealed that Tie2 expression is associated with the identification and prognosis of these cancer types (12). Ang1 is a secreted ligand for Tie2 that maintains vascular plasticity, perturbations in which can contribute to abnormal vascular growth (4). Daly et al (6) revealed that Ang2 functions as a Tie2 agonist in tumor models, limiting the effects of VEGF inhibition (6). Mitsutake et al (13) revealed ...

show abstract

“…Both factors are competitive ligands for tyrosine kinase (Tie-2), which is a receptor discovered on vessel endothelial cells, and form a dynamic balance system for regulation of angiogenesis (Suri et al 1996;Davis et al 1996;Maisonpierre et al 1997). Previous studies had performed to reveal the significances of Ang-1 and Tie-2 on many types of cancer (Caine et al 2003;Niedźwiecki et al 2006;Park et al 2009). Our study only focused on Ang-2, but not included Ang-1 and Tie-2.…”

Section: Chemotherapy Response No Of Patients (N)mentioning

confidence: 99%

Elevated Serum Level of Angiopoietin-2 as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer

Zhang

Yang

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is a fast-growing cancer with poor prognosis. Patients with extensive-stage SCLC are generally treated with chemotherapy. Thus, it is essential to identify a predictor of efficacy and prognosis for SCLC. Angiopoietin-2 promotes vascular remodeling and angiogenesis. Increasing evidence reveals that angiopoietin-2 is preferentially expressed in cancer cells, and elevated angiopoietin-2 expression is related to invasive and metastatic phenotypes in various cancers. However, serum angiopoietin-2 level and its prognostic potential in SCLC have not been investigated. The aim of this study was to determine the usefulness of angiopoietin-2 level as a predictor of efficacy and prognosis for SCLC. This study consisted of sixty patients with SCLC. Each patient received four cycles of cisplatin-etoposide chemotherapy, and was followed for 36 months. Serum angiopoietin-2 levels were measured by Enzymelinked immunosorbent assays. The angiopoietin-2 levels were significantly higher in SCLC patients than those in healthy subjects (P < 0.001). The patients were divided into high-level group (32 patients, 2,923.9 ± 294.7 pg/ml) and low-level group (28 patients, 1,789.5 ± 355.1 pg/ml) according to the mean value of the angiopoietin-2 level (2,400 pg/ml). Compared with the patients in the high-level group, the patients in the low-level group showed remarkably survival advantage (P = 0.002). During chemotherapy, the patients in the low-level group showed better treatment response than the patients in the high-level group (P < 0.05). Therefore, angiopoietin-2 might be useful as a prognostic factor for SCLC and for predicting SCLC response to chemotherapy.

show abstract

Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers

Cited by 31 publications

References 32 publications

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Ang1/Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K/AKT pathway

Elevated Serum Level of Angiopoietin-2 as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer

Contact Info

Product

Resources

About